Skip to main content

Day: March 6, 2023

Gaia Reports Fourth Quarter and Full Year 2022 Results

BOULDER, Colo., March 06, 2023 (GLOBE NEWSWIRE) — Gaia, Inc. (NASDAQ: GAIA), a conscious media and community company, reported financial results for the fourth quarter and full year ended December 31, 2022. “After a challenging 2022, when both revenue and adjusted EBITDA only increased in the single digits due to the post COVID subscriber contraction experienced industry wide, we have started to experience member growth this year,” said Jirka Rysavy, Gaia’s CEO.  “During the last few months, we have eliminated over $5 million in annualized spending, which includes 36 headcount that were added over the past two years to offset reduced efficiency because of work-from-home mandates. We expect to see the benefits of such savings begin during the second quarter.  In 2023, we plan to launch Gaia Marketplace, an initiative focused on...

Continue reading

CVG Reports Fourth Quarter and Full Year 2022 Results

Fourth quarter sales of $235 million, a 2.6% increase year-over-year Net loss $32.0 million, adjusted EBITDA of $13.3 million, a 3.1% increase in adjusted EBITDAContinued price realization to offset inflation Business transformation continues, record annual sales of $982 million In 2023, Company expects to realize ~$150 million in new business revenueStrong free cash flow and debt paydown exceeded target at ~$43 million NEW ALBANY, Ohio, March 06, 2023 (GLOBE NEWSWIRE) — CVG (NASDAQ: CVGI), a diversified industrial products and services company, today announced financial results for its fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 Highlights (Compared with prior-year period, where comparisons are noted)Revenue of $234.9 million, up 2.6% as demand and price increases came through as expected. New business...

Continue reading

RxSight, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

ALISO VIEJO, Calif., March 06, 2023 (GLOBE NEWSWIRE) — (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months and full year ended December 31, 2022. Key Quarterly and Full Year HighlightsRecognized fourth quarter 2022 revenue of $16.1 million, an increase of 91% compared to the fourth quarter of 2021, reflecting:The sale of 57 Light Delivery Devices (LDD™s), representing a 27% unit increase from the fourth quarter of 2021, expanding the installed base to 400 LDDs at the end of the quarter, a 94% increase compared to the 206-unit LDD installed base at the end of the fourth quarter of 2021; and The sale of 9,123 Light Adjustable Lenses (LAL®s), representing a...

Continue reading

HighPeak Energy, Inc. Announces Fourth Quarter 2022 Results and Reaffirms 2023 Outlook

FORT WORTH, Texas, March 06, 2023 (GLOBE NEWSWIRE) — HighPeak Energy, Inc. (“HighPeak” or the “Company”) (NASDAQ: HPK) today announced financial and operating results for the fourth quarter 2022 and reaffirmed its 2023 outlook.   HighlightsFourth quarter 2022 sales volumes averaged 37,348 barrels of crude oil equivalent per day (“Boe/d”), an increase of approximately 42% and 151% compared with third quarter 2022 and fourth quarter 2021, respectively, consisting of approximately 85% crude oil and 94% liquids. Fourth quarter 2022 exit sales volumes were approximately 39,900 Boe/d, an increase of approximately 172% year over year. EBITDAX (a non-GAAP financial measure defined and reconciled below) was $220.9 million and $577.1 million for the three months and year ended December 31, 2022, respectively. The Company’s year-end 2022...

Continue reading

Dave Inc. Announces Fourth Quarter and Full Year 2022 Results

Q4 Record GAAP Revenue Grew 45% Year Over YearQ4 Transaction Based Revenue Grew 88% Year Over YearQ4 Net Loss and Adj. EBITDA Improved by 55% and 59%, Respectively, From Q3 2022Q4 28-Day Delinquency Rate Improved ~50 Basis Points From Q3 2022 LOS ANGELES, March 06, 2023 (GLOBE NEWSWIRE) — Dave Inc. (the “Company”) (Nasdaq: DAVE, DAVEW), one of the leading U.S. neobanks, today reported its financial results for the fourth quarter and full year ended December 31, 2022. “We generated record top-line results during the quarter, achieved both our revenue and margin targets for the year, and significantly reduced losses as we exited 2022,” said Jason Wilk, founder and Chief Executive Officer of Dave. “During the fourth quarter, we reduced our customer acquisition cost by 31% and added 543,000 net new members, which, in conjunction with...

Continue reading

Calavo Growers, Inc. Announces First Quarter 2023 Financial Results

SANTA PAULA, Calif., March 06, 2023 (GLOBE NEWSWIRE) — Calavo Growers, Inc. (Nasdaq-GS: CVGW), a global avocado-industry leader and provider of convenient, ready-to-eat fresh food, today reported its financial results for the fiscal first quarter ended January 31, 2023. First Quarter Financial OverviewTotal revenue of $226.2 million, an 18% decline from prior yearGrown segment revenue decreased 27% year-over-year to $117.7 million Prepared segment revenue decreased 3% year-over-year to $108.5 millionGross profit of $14.4 million, compared to $13.2 million for the year-ago quarterGrown segment gross profit decreased $2.2 million from prior year to $9.5 million Prepared segment gross profit increased $3.4 million from prior year to $5.0 millionNet loss of $(3.1) million, or $(0.17) per diluted share, compared to net...

Continue reading

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

SAN CARLOS, Calif., March 06, 2023 (GLOBE NEWSWIRE) — Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022. The Company’s most advanced antibodies are lirentelimab (AK002) and AK006. Recent Allakos EventsInitiated a Phase 2b randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with chronic spontaneous urticaria (CSU) in the third quarter of 2022. Continued enrollment of a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with moderate-to-severe atopic dermatitis during the fourth quarter of 2022. Completed IND-enabling...

Continue reading

Ocular Therapeutix™ Provides Fourth Quarter and Year-End 2022 Results and Corporate Update

Presented Positive 10-month Interim Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Wet AMD at the Angiogenesis, Exudation, and Degeneration Annual 2023 Meeting Initiated Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Diabetic Retinopathy in December 2022 Top-Line Data from Phase 2 Clinical Trial of OTX-TIC (travoprost intracameral implant) for the Treatment of Patients with Primary Open-Angle Glaucoma or Ocular Hypertension Expected in Q4 2023 Total Net Revenue for Full Year 2022 was $51.5 million, Representing Growth of 18% Over the Prior Year DEXTENZA® Net Product Revenue in the Fourth Quarter of 2022 was $13.9 million, Representing Growth of approximately 17% Over Previous Quarter and 14% Over Comparable Quarter of 2021 DEXTENZA...

Continue reading

Hoylu AB (publ) provides an update on the previously announced tax surcharge

On 23 November 2022, Hoylu AB (publ) (“Hoylu” or the “Company”) announced a provision of SEK 4,475,000 due to a potential tax surcharge. The Swedish Tax Agency has now informed Hoylu of its decision to impose the Company with a tax surcharge of the said amount. The Company intends to appeal the decision. As published through a press release on 23 November 2022, Hoylu made a provision of SEK 4,475,000 due to a potential tax surcharge as a result of an ongoing tax audit by the Swedish Tax Agency. The Swedish Tax Agency has now resolved to impose the Company with a surcharge of SEK 4,475,000. The decision from the Swedish Tax Agency can be appealed until 27 March 2023. The Company intends to appeal the decision. For more information, please contact: Truls Baklid, CEO Hoylu AB Tel: +47 924 38 900 Email: tob@hoylu.com Certified Adviser: Mangold...

Continue reading

Nokia Corporation: Repurchase of own shares on 06.03.2023

Nokia CorporationStock Exchange Release6 March 2023 at 21:00 EET Nokia Corporation: Repurchase of own shares on 06.03.2023 Espoo, Finland – On 6 March 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows:Trading venue (MIC Code) Number of shares Weighted average price / share, EUR*XHEL 238,628 4.54CEUX 12,003 4.53AQEU 3,838 4.54TQEX 8,031 4.53Total 262,500 4.54* Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.